Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel + losartan followed by stereotactic radiotherapy for locally advanced pancreatic cancer
2022-001939-88Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of losartan, gemcitabine and paclitaxel in pancreatic cancer (PC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Treatment discontinuation due to treatment-related grade 3 or higher adverse events. Started Nov 2022; status: terminated.
02
Drugs
losartangemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2022-001939-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001939-88.